- Health Canada has authorized Core One Labs (COOL) to add DMT to its Controlled Drugs and Substances Act Dealer’s License
- The approval allows Core One subsidiary Vocan Biotechnologies to research and produce a proprietary DMT compound
- The company hopes to expedite the production of this compound using the same platform it used to produce API-grade psilocybin
- Core One Labs is focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy
- Core One (COOL) is up by 31.41 per cent trading at $2.05 per share
Health Canada has authorized Core One (COOL) to add DMT to its Controlled Drugs and Substances Act Dealer’s License.
The approval allows subsidiary Vocan Biotechnologies to produce a proprietary N,N-Dimethyltryptamine (DMT) compound.
Vocan’s scientists believe that the recombinant enzyme fermentation platform they used to produce API-grade psilocybin can produce stereochemically sound biosynthesized DMT at scale.
The replication of historical research and development processes also increases the probability of Core One filing a patent for its DMT compound in the near term.
“As we expect completion of the process for psilocybin in the upcoming days, we believe that we can fast-track the process for DMT, as it uses the same steps to biosynthesize the compounds,” stated Joel Shacker, Core One’s CEO. “Our team of leading scientists have done an amazing job in getting us to this stage and we are excited about the results we are seeing.”
Core One Labs is focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy.
Core One (COOL) is up by 31.41 per cent trading at $2.05 per share as of 2:29 pm EST.
